Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Nature 508 (7495), 258262
Our trainers will provide comprehensive instruction and guidance throughout the course
The modified form (AOD-9604) was pursued by Metabolic Pharmaceuticals through Phase 2 obesity trials but did not progress to full approval
Lead Researcher Spotlight Professor Frank Ng, PhD Department of Biochemistry and Molecular Biology Monash University, Melbourne, Australia Professor Frank Ng led the pioneering research team that developed AOD-9604 in the 1990s as part of efforts to create a targeted anti-obesity therapeutic derived from human growth hormone
2001 Most common overdose symptoms / injection-site erythema, transient headache, mild nausea IGF-1 elevation risk / not observed at doses up to 1 mg/day in Phase IIb data Emergency action / stop dosing, call Poison Control (1-800-222-1222), seek ER if chest pain or dyspnea occurs Antidote / none exists
